David Steensma, MD
@davidsteensma
Hematologist-oncologist. @AjaxThx CMO. Former Edward P. Evans Chair in MDS @DanaFarber, @HarvardMed & @MayoClinic faculty, @NovartisScience hematology head.
ID: 2739065578
10-08-2014 14:36:07
7,7K Tweet
25,25K Followers
460 Following
Yet another failed randomized trial of HMA combination in higher risk #MDSsm, this time with RARA agonist tamibarotene: n=245, CR rate 23.8% with combo vs 18.8% HMA alone, p=0.20. This is becoming a depressing and recurring theme, Amer Zeidan MBBS,MHS عامر زيدان. ir.syros.com/press-releases…